L Brands Reports December 2016 Sales and Updates Fourth Quarter Earnings Guidance
Jan 05, 2017 12:15 pm UTC| Business
COLUMBUS, Ohio, Jan. 05, 2017 -- L Brands, Inc. (NYSE:LB) reported net sales of $2.438 billion for the five weeks ended Dec. 31, 2016, an increase of 1 percent, compared to net sales of $2.415 billion for the five weeks...
Jan 05, 2017 12:05 pm UTC| Business
SAN RAMON, Calif., Jan. 05, 2017 -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical...
EndoPredict® Reviewed by Blue Cross Blue Shield Association’s Evidence Street
Jan 05, 2017 12:05 pm UTC| Business
SALT LAKE CITY, Jan. 05, 2017 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced that Evidence Street has reviewed EndoPredict®, Myriad’s second-generation test to predict...
Voyager Therapeutics Elects Wendy Dixon, Ph.D. and Glenn Pierce, M.D., Ph.D. to Board of Directors
Jan 05, 2017 12:05 pm UTC| Business
CAMBRIDGE, Mass., Jan. 05, 2017 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today...
Pure Energy Minerals Successfully Reaches Target Depth in CV-7
Jan 05, 2017 12:02 pm UTC| Business
VANCOUVER, British Columbia, Jan. 05, 2017 -- Pure Energy Minerals Limited (TSX-V:PE) (FRANKFURT:A111EG) (OTCQB:PEMIF) (the “Company” or “Pure Energy”) is pleased to announce that exploration borehole CV-7 has been...
Jan 05, 2017 12:01 pm UTC| Business
The new research collaboration follows previous non-clinical studies conducted with Denmark’s Aarhus University and is designed to identify additional high affinity molecular targets of MESUPRON (upamostat)Further...
Jan 05, 2017 12:01 pm UTC| Business
The new research collaboration follows previous non-clinical studies conducted with Denmark’s Aarhus University and is designed to identify additional high affinity molecular targets of MESUPRON (upamostat)Further...